+7%

est. 2Y upside i

HealthcareSeries B

Enable collaborates with the world’s leading researchers to construct detailed and searchable maps of complex diseases, making possible the exploration, navigation, and discovery of underlying biologi

Rank

#3514

Sector

Biotechnology

Est. Liquidity

~0Y

Data Quality

Data: Medium

Enable Medicine was acquired by General Inception in December 2024 for an undisclosed amount, fundamentally changing the equity opportunity.

Last updated: March 10, 2026

Bull (22%)+100%

The acquisition by General Inception was at a significant premium, valuing Enable Medicine at approximately $540M, reflecting the strong competitive moat and high growth potential of its AI-led generative biological search platform. This outcome provided substantial returns for common shareholders.

Base (50%)+10%

Enable Medicine was acquired by General Inception at a valuation of approximately $297M, slightly above its estimated Series A post-money valuation of $270M. This outcome provided modest returns for common shareholders, aligning with the company's strong technology but also reflecting the inherent risks of an early-stage acquisition.

Bear (28%)-70%

The undisclosed acquisition price by General Inception was at or below Enable Medicine's estimated Series A valuation of $270M. Given the $63.6M in liquidation preferences, common shareholders likely saw little to no return, as the acquisition served more as a strategic integration than a high-value exit for prior equity holders.

Est. time to liquidity~0.0 years

Preference Stack Risk

high

Prior investors contributed $63.6M (Seed $3.62M, Series A $60M), representing 23.5% of the estimated $270M Series A post-money valuation, indicating a high preference stack ahead of common shareholders.

Dilution Risk

moderate

As part of General Inception, future funding rounds for the parent company could lead to further dilution for equity holders.

Secondary Liquidity

none

Enable Medicine no longer exists as an independent entity, and there is no active secondary market for its former shares or for General Inception's private equity.

Engineering — 5 roles

Marketing — 4 roles

Success & Services — 3 roles

View all 16 open roles at Enable →

Last updated: February 22, 2026

Questions to Ask at the Interview

Strategic questions based on Enable's data — designed to show you've done your homework.

  • 1

    “Given Enable Medicine's acquisition by General Inception, how is the combined entity leveraging Enable's proprietary biological atlas and AI capabilities to accelerate drug discovery, and what are the key integration milestones for the next 12-24 months?”

  • 2

    “Enable Medicine had a strong competitive moat with its generative biological search. How does General Inception plan to maintain and expand this moat against potential in-house AI platforms from large pharmaceutical incumbents?”

  • 3

    “Considering Enable Medicine's acquisition in late 2024, what is General Inception's long-term vision for the Enable unit, and how does the equity package for new hires reflect the growth and liquidity strategy for the broader General Inception portfolio?”

Community

Valuation Sentiment

Our model estimates +7% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.